Is CervoMed Inc. (CRVO) overvalued? · rev $9.7M
CervoMed Inc. (CRVO) is a biotechnology company listed on US.
This page asks whether CervoMed Inc. (CRVO) looks expensive on cached numbers — not a short thesis.
Latest reported CRVO revenue for 2024-12-31 was $9.7M. Net income was -$16.3M. Revenue was up 36.3% from 2023-12-31 to 2024-12-31. CRVO currently screens at market cap $28.8M.
CRVO currently screens at market cap $28.8M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CRVO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CRVO stock page for the full model, not this heading.
Not investment advice.